Navigation Links
Repligen Announces Conference Call to Update Orencia(R) Lawsuit

Tuesday, April 8th, 9:00 a.m. EDT

WALTHAM, Mass., April 7, 2008 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) announced today that the Company President and Chief Executive Officer, Walter C. Herlihy, Ph.D., will host a conference call and webcast on Tuesday, April 8th, 2008 at 9:00 a.m. EDT, to provide an update on the Orencia(R) lawsuit.

This call is being webcast by Thomson/CCBN and can be accessed via Repligen's website at If you are unable to access the webcast via the internet, you may also listen to the live broadcast by calling (866) 314-4865 for domestic calls and (617) 213-8050 for international calls. Participants must provide the following passcode: 84470724. For those who cannot participate in the live conference call, an archive of the audio webcast will be available shortly after the call and may be accessed at

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for diseases that affect the central nervous system. In addition, we are the world's leading supplier of recombinant Protein A, the sales of which partially fund the advancement of our development pipeline while supporting our financial stability. Repligen's corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information may be requested from

This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, statements regarding current or future financial performance and position, management's strategy, plans and objectives for future operations, plans and objectives for product development, plans and objectives for present and future clinical trials and results of such trials, plans and objectives for regulatory approval, litigation, intellectual property, product development, manufacturing plans and performance such as the anticipated growth in the monoclonal antibody market and our other target markets and projected growth in product sales, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: the success of current and future collaborative relationships, the market acceptance of our products, our ability to compete with larger, better financed pharmaceutical and biotechnology companies, new approaches to the treatment of our targeted diseases, our expectation of incurring continued losses, our uncertainty of product revenues and profits, our ability to generate future revenues, our ability to raise additional capital to continue our drug development programs, the success of our clinical trials, our ability to develop and commercialize products, our ability to obtain required regulatory approvals, our compliance with all Food and Drug Administration regulations, our ability to obtain, maintain and protect intellectual property rights for our products, the risk of litigation regarding our intellectual property rights, our limited sales and manufacturing capabilities, our dependence on third-party manufacturers and value added resellers, our ability to hire and retain skilled personnel, our volatile stock price, and other risks detailed in Repligen's filings with the Securities and Exchange Commission. Repligen assumes no obligation to update any forward-looking information contained in this press release or with respect to the announcements described herein.

SOURCE Repligen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Repligen Elects Earl Henry, M.D. to the Board of Directors
2. Repligen to Present at Upcoming Healthcare Conferences Wednesday, November 28th and Wednesday, December 5th
3. Repligen Reports Second Quarter Fiscal Year 2008 Financial Results
4. AORN Announces Initiative to Develop a Standardized Electronic Healthcare Record for the Perioperative Setting
5. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of WellPoint, Inc. Who Invested in the WellPoint Retirement Savings Plan
6. Telik Announces Preclinical Presentations at AACR Annual Meeting
7. DARA Announces Information in Compliance with NASDAQ Rules
8. Journey Lite of Thousand Oaks Announces Special Spring Price Discount In Response to Effects of Softening Economy on Patients Pocketbooks
9. VA Announces SGLI and VGLI Premium Reductions
10. London Luxury LLC Announces Exclusive Partnership with Cupron, Inc., to Develop Innovative Copper-Infused Bed and Bath Products
11. Boston Scientific Announces Appointment of Timothy Pratt as General Counsel
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... CURE Media Group, ... announced a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) ... lymphoma, their families and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... beverage companies in the United States, today announced the release of its limited ... and new Cranberry Cocktail Agua Fresca. All feature the unique flavor combinations and ...
(Date:10/13/2015)... ... October 13, 2015 , ... HealthAware , ... HIMSS’s Patient Engagement Summit . HealthAware is a technology company focused on ... and interventions via mobile devices that provide a framework for the development of ...
(Date:10/13/2015)... ... 2015 , ... ProText Kinetic Panel is a typography creation tool made for ... create energetic text animations in any layout without the use of keyframes. Using ProText ... and stylize the text. With intuitive on-screen controls, users can re-position and scale the ...
(Date:10/13/2015)... ... October 13, 2015 , ... Symposium Chairman, Dr. Rod J. ... Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The annual meeting, ... plastic surgeons and cosmetic physicians from around the world. , Key topics at this ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... COLLEGE PARK, Md. , Oct. 13, 2015 ... hubs is the biggest key to growing Baltimore ... to a report released today by the Maryland Technology ... already has many of the pieces in place to support ... Martha Connolly , director of Mtech Baltimore. "This study is ...
(Date:10/13/2015)... 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... company serving the pharmaceutical, biotechnology, and medical device ... mobile version of OncoWuXi, the first App in ... models and data on the go.  The OncoWuXi ... time to identify relevant tumor models for use ...
(Date:10/13/2015)... Oct. 13, 2015 Health Gorilla ( ) ... Network – a secure platform for clinical data and ... interact about and manage healthcare in the US. The launch ... for a combined total of $4.4M raised to date, with ... True Ventures , Harris Barton , Orfin ...
Breaking Medicine Technology: